OmniAb (OABI) Shares Outstanding (2021 - 2026)
OmniAb (OABI) posted quarterly Shares Outstanding (Entity) of $144.8 million for Q1 2026, up 18.54% year-over-year from $122.1 million in Q1 2025, and up 27.41% quarter-over-quarter from $113.6 million in Q4 2025.
OmniAb (OABI) Shares Outstanding (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Shares Outstanding (Entity) for 6 consecutive years, with $144.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 18.54% year-over-year to $144.8 million; the TTM figure through Mar 2026 stood at $144.8 million (up 18.54% YoY), while the FY2025 annual figure was $113.6 million, down 6.55% from the prior year.
- Shares Outstanding (Entity) grew to $144.8 million in Q1 2026 per OABI's latest filing, from $113.6 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $144.8 million in Q1 2026 and bottomed at $23.0 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $100.9 million across 5 years, with a median of $116.2 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) soared 405.36% — and 2025, when it fell 6.55%.
- OmniAb's Shares Outstanding (Entity) stood at $85.3 million in 2022, then soared by 36.97% to $116.9 million in 2023, then advanced by 4.06% to $121.6 million in 2024, then dropped by 6.55% to $113.6 million in 2025, then advanced by 27.41% to $144.8 million in 2026.
- Business Quant data shows OABI's Shares Outstanding (Entity) at $144.8 million in Q1 2026, $113.6 million in Q4 2025, and $114.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | 128.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.80 Mn |
| Mar 31, 2026 | 128.25 Mn |
| Dec 31, 2025 | 113.64 Mn |
| Sep 30, 2025 | 114.73 Mn |
| Jun 30, 2025 | 106.15 Mn |
| Mar 31, 2025 | 105.62 Mn |
| Dec 31, 2024 | 102.37 Mn |
| Sep 30, 2024 | 102.39 Mn |
| Jun 30, 2024 | 101.46 Mn |
| Mar 31, 2024 | 100.76 Mn |
| Dec 31, 2023 | 99.68 Mn |
| Sep 30, 2023 | 99.91 Mn |
| Jun 30, 2023 | 99.49 Mn |
| Mar 31, 2023 | 99.16 Mn |
| Dec 31, 2022 | 85.32 Mn |
| Sep 30, 2022 | 23.00 Mn |
| Jun 30, 2022 | 23.00 Mn |
| Mar 31, 2022 | 23.00 Mn |
| Dec 31, 2021 | 82.61 Mn |
| Sep 30, 2021 | 17.65 Mn |